Mendelian randomization is often described as a natural experiment written into the genome. The method uses genetic variants associated with an exposure—such as a molecular marker or a physiological characteristic—as instrumental variables. Because genetic variants are assigned before birth and are generally less influenced by later behavior or disease, they can sometimes help distinguish correlation from causation in observational data. In a conventional analysis, however, each outcome is usually treated separately. That strategy can discard information when outcomes are biologically related and statistically correlated. It can also make the analysis less powerful, because the evidence is divided among multiple tests. “Correlated outcomes” might include the expression levels of several genes controlled by a common regulatory mechanism, or a collection of clinical traits that share underlying biology. The new framework treats those outcomes as a connected system rather than as unrelated endpoints.

The researchers introduce two complementary tools. The first, called multivariate inverse-variance weighted Mendelian randomization, or multivariate MR-IVW, extends a widely used method for combining genetic evidence. In ordinary inverse-variance weighting, estimates from individual genetic instruments are weighted according to their precision: variants with smaller uncertainty contribute more to the overall result. The multivariate version additionally models the covariance among outcome estimates. In practical terms, it knows that measurements of two related genes may rise and fall together, and it adjusts the calculation accordingly. The method uses multivariate meta-analysis, a statistical technique that combines several outcomes while retaining information about their correlations. This “borrowing of strength” can reduce noise and improve the accuracy of the estimated causal effects, provided that the covariance structure is estimated appropriately.

The second tool, multivariate MR-PRESSO, addresses one of the most persistent hazards in Mendelian randomization: horizontal pleiotropy. A genetic variant is a useful instrument only when its effect on an outcome operates through the exposure being studied. But some variants affect several biological pathways directly. Such variants can distort a causal estimate, even when the exposure-outcome association appears convincing. Existing MR-PRESSO analyses can identify instruments that behave unusually for one outcome at a time. The multivariate extension evaluates the pattern across all outcomes simultaneously. It uses Mahalanobis distance, which measures how far a vector of observations lies from the expected multivariate pattern while accounting for correlations among variables. An instrument can therefore be flagged not merely because it looks extreme for one gene, but because its combined effects across several genes are inconsistent with the causal model.

To test the performance of the methods, the team conducted extensive simulations in which the underlying causal effects, correlations among outcomes and levels of pleiotropy could be controlled. The simulations showed that multivariate MR-IVW consistently produced lower bias and lower mean squared error than the corresponding univariate approach. Bias is the systematic tendency of an estimator to miss the true value, while mean squared error combines that bias with random variation and is a standard measure of overall estimation quality. The advantage became especially striking when outcomes were strongly correlated. In a global hypothesis test involving two outcomes with a correlation of 0.8, the multivariate MR-IVW method detected an effect in 95 percent of relevant simulated cases, compared with 52 percent for the univariate method. At the same time, the researchers report that false-positive rates remained controlled, an essential safeguard when greater sensitivity can otherwise produce spurious discoveries.

The simulations also revealed a substantial gain in the detection of problematic genetic instruments. With four correlated outcomes and balanced pleiotropy—when a variant’s unintended effects push in opposing directions—the multivariate MR-PRESSO procedure identified outlying single-nucleotide polymorphisms in roughly 85 to 90 percent of simulated cases. The comparable univariate analysis detected them only 35 to 40 percent of the time. This difference matters because pleiotropic variants can be difficult to recognize when their effects are modest for any individual outcome. Across several outcomes, however, those small deviations may form a distinctive multivariate signature. Mahalanobis distance captures that joint departure, increasing the chance that a researcher will investigate or remove an instrument before it biases the final conclusion. The method does not eliminate the assumptions of Mendelian randomization, but it provides a more systematic stress test for them.

The researchers next applied their methods to a real multi-omics question involving DNA methylation at a genomic site known as cg11294513 and the expression of five zinc-finger genes. DNA methylation is a chemical modification in which methyl groups are added to DNA, often near regulatory regions. It can influence whether genes are active, although its effects depend on genomic location, cell type and surrounding molecular context. Zinc-finger proteins are a large family of proteins that can bind DNA and help regulate gene activity, making them important components of cellular control systems. The analysis combined data from the Framingham Heart Study with gene-expression information from the Genotype-Tissue Expression project, or GTEx. Together, these resources allowed the team to examine whether genetically predicted variation in methylation at cg11294513 was causally related to the activity of the five genes.

The multivariate analysis found significant causal effects of methylation at cg11294513 on all five zinc-finger gene-expression outcomes. The joint approach also identified additional heterogeneous instruments that were not detected when the genes were analyzed individually. In this context, heterogeneity means that the genetic instruments do not all support a single coherent causal pattern; some may be influenced by alternative pathways or may behave differently because of biological complexity. Identifying those instruments is crucial before interpreting a molecular association as causal. The finding does not by itself establish that changing methylation at cg11294513 would produce a specific health benefit, nor does it demonstrate that the five genes form a single linear pathway. Rather, it shows how a coordinated statistical analysis can reveal a shared regulatory signal and expose genetic evidence that deserves closer examination.

The approach arrives as genetic studies increasingly move beyond one-exposure, one-outcome questions. Large association studies now measure thousands of molecular traits, while researchers seek to understand how regulatory changes propagate through cells and eventually contribute to disease. Analyzing each outcome independently can create a maze of separate significance tests, reduce statistical power and obscure patterns that are visible only at the system level. Multivariate MR-IVW offers a way to estimate several related effects together, while multivariate MR-PRESSO provides a corresponding method for identifying instruments that do not fit the overall pattern. The framework may therefore be valuable in studies of gene regulation, multimorbidity and other settings where biological outcomes are intrinsically linked. Its usefulness will depend on reliable estimates of outcome correlations, strong and valid genetic instruments, and careful attention to the possibility that the same participants or datasets contribute to multiple measurements.

The authors provide R code for the multivariate MR-PRESSO method and their simulation study, while the multivariate MR-IVW analysis was implemented using the mvmeta package, which supports fixed-effects and random-effects multivariate meta-analysis. These resources could make the methods easier to evaluate and adapt, but the statistical gains should not be mistaken for a replacement for experimental validation. Mendelian randomization remains dependent on core assumptions: the genetic instruments must be associated with the exposure, must not be related to important confounders, and must influence the outcomes primarily through the exposure rather than through independent pathways. Correlated outcomes can strengthen inference when modeled correctly, but they can also amplify errors if the correlation structure or causal model is wrong. Even so, by turning the relationships among multiple outcomes from a nuisance into usable information, the new framework offers a potentially powerful upgrade for the next generation of causal genetic research—one capable of following biological signals across an entire molecular network instead of stopping at a single gene.

Fabry disease is an inherited condition caused by mutations in the GLA gene. These mutations reduce or eliminate the activity of α-galactosidase A, an enzyme required to break down globotriaosylceramide and related lipids inside cells. When the enzyme is deficient, these substances accumulate within lysosomes, the cell’s recycling compartments. The resulting storage is especially damaging in tissues such as the vascular endothelium, kidney, heart, and nervous system. Fabry disease is X-linked, meaning that it can affect males and females, although the severity and pattern of symptoms can vary substantially even among people carrying similar genetic variants.

For decades, the central explanation of Fabry disease focused on substrate accumulation. The review emphasizes that storage is only the first step in a much broader cascade of cellular disruption. Lipid accumulation can interfere with organelle function, alter membrane signaling, and activate inflammatory pathways. Oxidative stress may damage proteins, DNA, and cellular membranes, while mitochondrial dysfunction can reduce energy production in tissues with high metabolic demands. Abnormal signaling, immune activation, fibrosis, and changes in cell death pathways may then reinforce one another, gradually transforming a biochemical defect into irreversible organ damage.

Multi-omics technologies are allowing scientists to observe these changes at several biological levels simultaneously. Transcriptomics measures patterns of RNA expression, showing which genes are switched on or off in diseased tissue. Proteomics examines changes in proteins, including enzymes, receptors, structural molecules, and signaling factors. Metabolomics captures shifts in small molecules that reflect the state of cellular metabolism. When combined with lipidomics, epigenomics, and single-cell analysis, these methods can identify disease-associated signatures that may be invisible when researchers study only one molecule or pathway at a time.

The kidneys are among the most vulnerable organs in Fabry disease. Specialized cells called podocytes help maintain the filtration barrier that prevents large proteins from escaping into urine. Storage material and secondary stress can injure these cells, leading to proteinuria, scarring, and declining filtration capacity. The review highlights evidence that disrupted energy metabolism, complement activation, immune-cell signaling, and ferroptosis may contribute to renal injury. Ferroptosis is an iron-dependent form of regulated cell death associated with oxidative damage to cell membranes. Understanding how these pathways interact could help explain why kidney disease sometimes progresses despite treatment.

Cardiac involvement is another major cause of illness and premature death. Fabry disease can produce left ventricular hypertrophy, in which the muscular wall of the heart becomes abnormally thick, as well as fibrosis, rhythm disturbances, and heart failure. Multi-omics findings point to several contributors, including oxidative stress, defective mitochondrial energy production, altered lipid handling, and abnormal protein trafficking. These mechanisms may help explain why a heart can continue to deteriorate even when therapy reduces the primary storage burden. Detecting molecular signs of cardiac injury before extensive fibrosis develops could become an important goal for future clinical care.

The nervous system is affected through multiple routes. Patients may experience burning or chronic pain, reduced sensitivity, gastrointestinal and autonomic symptoms, transient ischemic attacks, or stroke. Vascular abnormalities can restrict blood flow, while inflammation and oxidative damage may directly disrupt neurons and supporting cells. Changes in nerve signaling and small-fiber function can produce pain that is difficult to control. By mapping gene activity, proteins, and metabolites in affected tissues and blood, researchers hope to distinguish the biological pathways responsible for different neurological symptoms rather than treating them as a single uniform complication.

The review also places Fabry disease within a rapidly expanding therapeutic landscape. Enzyme replacement therapy supplies a manufactured form of α-galactosidase A, helping cells clear accumulated substrates, although responses can differ and treatment does not always reverse established organ damage. Pharmacological chaperones can stabilize certain mutant forms of the enzyme and improve their delivery to lysosomes in eligible patients. Substrate reduction therapy aims to decrease production of the molecules that accumulate, while gene therapy seeks to provide cells with a functional copy of GLA. Multi-omics may help determine which patients are most likely to benefit from each approach and identify biological signs of treatment response.

Important challenges remain before these technologies become routine tools in the clinic. Molecular signatures must be validated in large and diverse patient groups, standardized across laboratories, and connected to outcomes that matter to patients, such as kidney function, arrhythmia risk, or stroke. Researchers must also determine whether a biomarker reflects active, reversible injury or damage that has already become permanent. Even so, the review presents multi-omics as a powerful bridge between genetic diagnosis and precision medicine. By showing how metabolic storage, inflammation, mitochondrial failure, immune activity, and fibrosis converge across organs, the field is moving toward earlier intervention and a more detailed biological portrait of every person living with Fabry disease.

Subject of Research: Fabry disease, multi-omics, organ injury, biomarkers, and therapeutic development

Article Title: Pathophysiological mechanisms of organ injury in Fabry disease: Update via multi-omics

Web References: https://doi.org/10.1016/j.gendis.2025.101949

References: Zhiyuan Wei, Junlan Yang, Zhongyu Han, Xiaoliang Zhang, Bin Wang, “Pathophysiological mechanisms of organ injury in Fabry disease: Update via multi-omics,” Genes & Diseases, Volume 13, Issue 5, 2026, Article 101949.

Image Credits: Genes & Diseases

Keywords: Fabry disease, GLA gene, α-galactosidase A, multi-omics, transcriptomics, proteomics, metabolomics, kidney disease, cardiac disease, neuroinflammation, biomarkers, enzyme replacement therapy, gene therapy

Researchers led by Marc Dottermusch, Anna Ryba and Anja Gocke used a multi-omics strategy to examine corticotroph PitNETs at several biological levels simultaneously. Rather than relying on a single measurement, such as hormone production or the activity of selected genes, multi-omics combines different molecular datasets to create a more comprehensive portrait of disease. Depending on the datasets analysed, this approach can capture gene expression, genetic alterations, epigenetic marks, protein activity and other features that influence how a tumour behaves. By integrating these layers, the investigators identified four molecular subgroups with distinct clinicopathological characteristics.

The finding challenges the idea that corticotroph tumours represent one uniform disease. Under the microscope, many pituitary tumours may share broad features, and routine clinical tests often focus on hormone excess, tumour size, invasion and response to treatment. Molecular analysis, however, can reveal hidden differences in the biological programmes that drive tumour growth and hormone secretion. Two tumours that appear similar in a pathology laboratory may therefore depend on different signalling pathways, carry different risks or respond differently to therapy. The four-group classification provides a framework for making those distinctions visible.

At the centre of the research is the principle that tumour behaviour emerges from interacting molecular systems. DNA sequence changes may alter the instructions available to a cell, but those instructions are interpreted through epigenetic regulation, which controls whether genes are switched on or off. Gene activity is then translated into proteins and signalling networks that determine cell division, hormone synthesis, metabolism and interactions with surrounding tissue. Examining only one layer can miss important biological connections. Multi-omics integration instead searches for coordinated patterns across layers, allowing researchers to distinguish fundamental tumour programmes from isolated molecular abnormalities.

For corticotroph PitNETs, this distinction is especially important because ACTH production and tumour aggressiveness do not always move together. Some lesions produce substantial hormone excess while remaining relatively small, whereas others may grow invasively, recur after surgery or prove difficult to control despite less striking hormonal findings. The newly described subgroups were reported to have distinct clinicopathological features, indicating that their molecular identities correspond to observable differences in patients and tumour specimens. Such links are a crucial step toward translating molecular classification into practical medical decisions.

The study could also help explain why treatment outcomes vary. Surgery is the primary treatment for many patients with Cushing’s disease, but complete removal may be difficult when a tumour extends into nearby structures. Persistent or recurrent disease may require medication, radiation or additional surgery. Drugs that suppress cortisol production or interfere with ACTH-related pathways can be effective, but responses are not uniform. If particular molecular subgroups are associated with hormone production, invasive growth or recurrence, clinicians may eventually use tumour biology to estimate risk and select follow-up strategies more precisely.

Importantly, the classification is not simply a new set of labels. A useful molecular subgroup system must be reproducible, biologically meaningful and feasible to apply beyond a single research cohort. The researchers’ integration of multiple molecular datasets offers a basis for developing such a system, but further studies will be needed to test whether the four subgroups can be identified consistently in independent patient populations. Researchers will also need to determine whether the classification remains stable over time, particularly after treatment, and whether it predicts outcomes strongly enough to change clinical management.

The work illustrates the broader transformation taking place in cancer and endocrine research. Traditional tumour categories are increasingly being supplemented by molecular taxonomies that describe what a tumour is doing rather than only where it is located or how it looks. In pituitary medicine, this shift could be especially valuable because these tumours are uncommon, biologically diverse and closely linked to systemic hormone disturbances. A molecular map may help researchers connect cellular mechanisms to whole-body effects, revealing why a tumour triggers severe disease in one patient but follows a more restrained course in another.

For patients, the immediate message is not that clinical care will change overnight, but that the biological complexity of corticotroph PitNETs is becoming clearer. The identification of four molecular subgroups provides researchers with a more precise language for studying these tumours and a potential foundation for future biomarkers and targeted treatments. As independent studies validate the classification and connect each subgroup to therapeutic responses, multi-omics profiling could move from an advanced research tool toward a practical component of precision endocrinology. What once looked like a single disorder may, at the molecular level, be four different diseases requiring four different strategies.

Subject of Research: Corticotroph pituitary neuroendocrine tumours and their molecular classification using multi-omics integration.

Article Title: Multi-omics integration unravels four molecular subgroups of corticotroph pituitary neuroendocrine tumours with distinct clinicopathological features.

Article References: Dottermusch, M., Ryba, A., Gocke, A. et al. “Multi-omics integration unravels four molecular subgroups of corticotroph pituitary neuroendocrine tumours with distinct clinicopathological features.” Nature Communications 17, 7777 (2026). https://doi.org/10.1038/s41467-026-76292-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-026-76292-y

Keywords: corticotroph pituitary neuroendocrine tumours, Cushing’s disease, ACTH, pituitary tumours, multi-omics, molecular subgroups, precision medicine, tumour biology, endocrinology, cancer research

In a new study reported in Nature Water, researchers describe how quorum sensing (QS), a chemical language used by microbes to coordinate behavior, can deliberately reshape the fate of NOB and enable sustained nitritation. The work links cell-to-cell signaling to a specific gene expression program in the dominant NOB genus Nitrospira.

Using multi-omics analyses alongside single-cell Raman spectroscopy, the team found that QS signaling triggers overexpression of nirB in Nitrospira. nirB encodes a key component of nitrite reduction, suggesting that QS doesn’t merely slow NOB growth—it actively reroutes their metabolism toward an outcome that harms their own persistence.

The mechanism is described as “metabolic altruism.” QS-activated Nitrospira performs nitrite reduction in a way that ultimately leads to self-inactivation. In contrast, ammonia-oxidizing bacteria do not carry out this altruistic metabolism under the same signaling conditions, allowing them to maintain competitiveness and keep nitrification flux focused on nitritation rather than full oxidation.

To test causality, the researchers manipulated QS activity and observed that active QS is required for nitritation to remain stable. When QS was disrupted, nitritation deteriorated, reinforcing the idea that NOB behavior is not just correlated with signaling but depends on it.

Single-cell Raman measurements provided additional resolution, showing that QS pushes stressed Nitrospira into a more susceptible physiological state. As a result, survival drops sharply—an effect consistent with population-level suppression of NOB function.

Together, the findings reveal a previously unrecognized social behavior within nitrifying microbial communities: NOB can coordinate via QS to trigger a self-defeating strategy, creating a window for nitritation to dominate. Beyond basic biology, the study points toward QS-targeted control strategies that could help operators stabilize nitritation with greater reliability.

Subject of Research: Nitritation stabilization via quorum sensing in nitrifying communities
Article Title: Quorum sensing-driven metabolic altruism of nitrite-oxidizing bacteria fuels nitritation
Article References: Zhuang, X., Wang, X., Jiang, C. et al. Quorum sensing-driven metabolic altruism of nitrite-oxidizing bacteria fuels nitritation. Nat Water (2026). https://doi.org/10.1038/s44221-026-00677-y
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s44221-026-00677-y
Keywords: nitritation; quorum sensing; Nitrospira; nirB; metabolic altruism; single-cell Raman; nitrogen removal

The mitochondrion, often referred to as the powerhouse of the cell, holds a distinct genome and transcriptional profile crucial for cellular function, energy metabolism, and signaling. Understanding how mitochondrial RNAs differ, move, and dynamically interact within the mitochondrial environment holds immense importance for elucidating fundamental biological mechanisms and disease pathogenesis, including metabolic disorders, neurodegenerative diseases, and cancer. However, existing mitochondrial RNA profiling tools frequently encounter cellular complexity, resulting in signal contamination from cytoplasmic or nuclear RNAs, and require the introduction of exogenous genetic constructs, which complicates studies especially in primary cells or delicate biological samples.

The newly developed CAT-seq method deftly eliminates these barriers by leveraging a photocatalytic quinone methide (QM) probe designed explicitly for selective RNA labeling within mitochondria of living cells. Quinone methides, known for their reactive electrophilic character, have long been recognized for their capacity to form covalent bonds with nucleophiles, making them ideal for targeted biomolecular tagging. The research team’s novel application of QM chemistry, integrated with a bioorthogonal framework, ensures high efficiency and specificity in reacting with mitochondrial RNA while preserving the native physiological milieu of the cells.

Integral to the success of CAT-seq is the meticulous optimization and validation process performed by the researchers, who fine-tuned probe concentration, illumination parameters, and reaction conditions to maximize labeling efficiency and minimize off-target modification. The approach employs a mild photoactivation step that triggers the quinone methide warhead, enabling spatiotemporally controllable covalent attachment to RNA molecules within the mitochondrial matrix. This light-driven bioorthogonal chemistry confines labeling exclusively to molecules present at the precise location and time of illumination, enhancing spatial resolution and reducing background noise typical of diffusion-based labeling techniques.

Demonstrating the robustness of CAT-seq, the authors successfully applied the method to HeLa cells, a widely used human cell line. The experiments highlighted CAT-seq’s ability to map the mitochondrial transcriptome with subcellular precision, revealing nuanced patterns of RNA distribution and turnover. The technique also facilitated the real-time tracking of RNA dynamics, capturing changes in mitochondrial RNA profiles in response to cellular stimuli and environmental perturbations. These findings underscore the method’s potential to decipher mitochondrial RNA life cycles and their adaptive mechanisms under various physiological and pathological conditions.

Beyond conventional cancer cell models, CAT-seq was deployed to investigate RAW 264.7 macrophages, representing a more challenging and physiologically relevant immune cell type. Macrophages play pivotal roles in immune defense and inflammation, with mitochondrial function intricately linked to their activation states and metabolic rewiring. Using CAT-seq, the research unveiled an underlying mitochondrial translational remodeling pathway previously obscured in bulk transcriptomic studies. This discovery opens avenues to explore how mitochondrial transcriptomics influence immune responses and may aid in identifying novel therapeutic targets for inflammatory and infectious diseases.

A particularly remarkable aspect of this novel approach is the establishment of an orthogonal labeling system based on the distinctive chemistry of quinone methide warheads. By designing complementary chemistries that do not interfere with one another, the team achieved simultaneous labeling of both mitochondrial RNA and proteins within the same living cell sample. This synchronous multi-omics profiling provides a holistic view of mitochondrial molecular landscapes, linking transcriptomic information with proteomic insights to unravel coordinated regulatory networks. The ability to perform multi-omics investigations in situ and in live cells overcomes limitations of previous methods relying on cell disruption, fractionation, or genetic engineering.

This integrated multi-omics strategy significantly propels the options available for investigating complex biological phenomena where mitochondrial function is critical. For example, the interplay between mitochondrial gene expression and protein synthesis, critical for maintaining mitochondrial biogenesis and oxidative phosphorylation efficiency, can now be studied with remarkable spatiotemporal clarity. CAT-seq’s compatibility with intact primary living samples furthers its translational appeal, as conventional techniques often fail to capture the native mitochondrial transcriptomic state in these sensitive and heterogeneous biological matrices.

Furthermore, this study highlights the frontier interface of chemistry and cell biology, showcasing how innovative chemical biology tools can empower the life sciences community to answer long-standing questions about subcellular molecular organization. The use of photoactivatable quinone methide probes represents a paradigm shift, enabling precision manipulation and monitoring of RNA molecules localized within specific organelles under physiological conditions. This approach establishes a blueprint for future technologies aimed at resolving the complexity and dynamics of intracellular RNA populations with unparalleled resolution.

The implications of CAT-seq extend beyond mitochondrial studies as the fundamental principles of bioorthogonal photocatalytic labeling could be adapted to target other subcellular RNA populations and potentially other types of biomolecules in diverse living systems. This enhanced ability to dissect local transcriptomics will deepen insights into organelle-specific RNA processing, localization, and turnover, which are critical parameters in understanding cellular homeostasis, signaling, and disease progression.

On a technical note, the study details rigorous experimental controls validating the specificity of RNA labeling over DNA or protein counterparts and confirms minimal phototoxicity or perturbation of cellular viability. The authors also demonstrate the scalability of their technique, suggesting its compatibility with high-throughput sequencing workflows and its potential integration within existing omics pipelines. This scalability promises to accelerate widespread adoption and reproducibility across diverse research laboratories interested in subcellular omics.

The development of CAT-seq embodies the growing trend towards non-genetic and minimally invasive investigation techniques in cell biology, providing powerful alternatives to transgenic or viral labelling strategies, which carry inherent risks and technical barriers. Notably, the absence of genetic modification enhances the feasibility of applying CAT-seq directly to primary cells, stem cells, or clinical samples, thus bridging a significant gap between basic research and biomedical applications.

Moreover, the ability to capture real-time RNA profiles in live cells holds remarkable promise for studying temporal gene expression changes during dynamic biological processes such as differentiation, stress response, or disease progression. CAT-seq’s temporal resolution, governed by controllable photoactivation, allows for snapshots of RNA molecules at defined time points, enabling kinetic studies that were previously difficult to achieve with conventional RNA sequencing methods.

The versatility and precision of CAT-seq may also catalyze innovations in drug discovery and therapeutic monitoring, where mitochondrial dysfunction is implicated. By providing a sensitive readout of mitochondrial RNA alterations in response to pharmacological agents or environmental toxins, this method could facilitate the identification of mitochondrial biomarkers and enhance the screening of mitochondrial-targeted drugs.

This landmark study, therefore, not only provides a transformative tool for mitochondrial RNA research but also exemplifies how interdisciplinary approaches leveraging chemical biology, molecular biology, and advanced sequencing technologies can unveil hidden layers of cellular regulation. As the research community increasingly recognizes the importance of spatially resolved omics, CAT-seq stands out as a pioneering technique with vast potential to reshape our understanding of cellular architecture and function.

In summary, CAT-seq represents a monumental step forward in the capacity to profile mitochondrial RNA within living cells with high resolution, precision, and minimal invasiveness. By harnessing the power of bioorthogonal photocatalytic chemistry and innovative quinone methide probes, the method offers detailed insights into RNA localization, dynamics, and interplay with mitochondrial protein synthesis. This revolutionary technology promises to deepen our understanding of mitochondrial biology in health and disease and to foster novel discoveries across the biomedical sciences.

Subject of Research: Mitochondrial RNA profiling and synchronous multi-omics investigation using bioorthogonal photocatalytic labelling.

Article Title: Photocatalytic labelling-enabled subcellular-resolved RNA profiling and synchronous multi-omics investigation.

Article References:
Bi, Y., Yu, L., Deng, Q. et al. Photocatalytic labelling-enabled subcellular-resolved RNA profiling and synchronous multi-omics investigation. Nat. Chem. (2025). https://doi.org/10.1038/s41557-025-01946-1

Image Credits: AI Generated